HomeCompareANGN vs MO

ANGN vs MO: Dividend Comparison 2026

ANGN yields 200.00% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANGN wins by $119.28M in total portfolio value
10 years
ANGN
ANGN
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full ANGN calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ANGN vs MO

📍 ANGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANGNMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANGN + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANGN pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANGN
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, ANGN beats the other by $51,124,046.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANGN + MO for your $10,000?

ANGN: 50%MO: 50%
100% MO50/50100% ANGN
Portfolio after 10yr
$59.72M
Annual income
$30,103,127.72/yr
Blended yield
50.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ANGN
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
Price Target
$1.50
+50.0% upside vs current
Range: $1.50 — $1.50
Altman Z
-16.3
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANGN buys
0
MO buys
0
No recent congressional trades found for ANGN or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANGNMO
Forward yield200.00%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$119.36M$80.1K
Annual income after 10y$60,176,096.29$30,159.17
Total dividends collected$112.49M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$1.50$61.25

Year-by-year: ANGN vs MO ($10,000, DRIP)

YearANGN PortfolioANGN Income/yrMO PortfolioMO Income/yrGap
1← crossover$30,700$20,000.00$10,570$780.30+$20.1KANGN
2$90,232$57,383.18$11,381$1,032.90+$78.9KANGN
3$254,173$157,624.56$12,535$1,392.73+$241.6KANGN
4$686,927$414,961.74$14,193$1,920.91+$672.7KANGN
5$1,783,118$1,048,106.39$16,618$2,723.68+$1.77MANGN
6$4,450,613$2,542,677.12$20,263$3,993.80+$4.43MANGN
7$10,693,420$5,931,263.38$25,936$6,098.36+$10.67MANGN
8$24,760,608$13,318,648.86$35,166$9,775.01+$24.73MANGN
9$55,315,649$28,821,798.66$51,026$16,597.78+$55.26MANGN
10$119,363,841$60,176,096.29$80,113$30,159.17+$119.28MANGN

ANGN vs MO: Complete Analysis 2026

ANGNStock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Full ANGN Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ANGN vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANGN vs SCHDANGN vs JEPIANGN vs OANGN vs KOANGN vs MAINANGN vs PMANGN vs BTIANGN vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.